Objectives-Point shear wave elastography is a quantitative ultrasound-based imaging method used in the assessment of renal disease. Among point shear wave elastographic options, 2 techniques have been studied considerably: Virtual Touch quantification (VTQ; Siemens AG, Erlangen, Germany) and ElastPQ (EPQ; Philips Healthcare, Bothell, WA). Both rely on the tissue response to an acoustic beam generated by the ultrasound transducer. The data on renal VTQ are more extensive, whereas EPQ has been used less thus far in the assessment of the kidneys. This study aimed to evaluate the performance of EPQ in the kidney and compare it with VTQ.
C hronic kidney disease (CKD) represents an increasing epidemiologic burden, with a global prevalence of 11% to 13%, 1 and its detection in current medical practice relies mainly on biological markers. 2 Irrespective of the underlying etiology, CKD progresses with parenchymal fibrosis, tubulointerstitial atrophy, and sclerosis of the glomerular compartment. 3 These structural abnormalities as detected by conventional grayscale ultrasound (US) imaging are not objectively quantifiable. Therefore, a quantifiable noninvasive imaging method is needed.
Point shear wave elastography (SWE) is a novel method that includes the Virtual Touch quantification (VTQ; Siemens AG, Erlangen, Germany) and ElastPQ (EPQ; Philips Healthcare, Bothell, WA) techniques. 4 Shear waves produced by a push beam propagate in the tissue and are measured as the shear wave velocity (SWV) in meters per second. Both methods rely on the same physical principle, that of acoustic radiation force impulse imaging. 4 The VTQ method not only has been validated as a valuable tool in noninvasive prediction of liver fibrosis 5, 6 and portal hypertension 7 but also has been used in research on prostate, 8 thyroid, 9 and renal disease. A review by Wang 10 highlighted the complexity of point SWE evaluations of the kidney due to anisotropy and other confounders (age, underlying disease, and hemodynamic factors). However, the method has proven to be reproducible, 11 with kidney SWV values decreasing with renal disease progression. 12, 13 Where renal EPQ is concerned, the number of extensive original articles is quite limited. The method is performed in the same manner as the VTQ technique and is integrated in a conventional US machine. This method has shown its noninferiority in the diagnosis of liver fibrosis, [14] [15] [16] having been studied mainly in chronic viral hepatitis and cirrhosis. Our study aimed to evaluate the utility of EPQ elastography in the detection of CKD compared to participants with no renal disease and to compare it with VTQ elastography, which has been much more frequently studied.
Materials and Methods

Participants
In our study, we included 124 prospective participants: 102 (82%) with different stages of CKD, and 22 (18%) as healthy controls. Of these 124 participants, 91 were evaluated with both the EPQ and VTQ techniques. The patients with CKD were diagnosed on the basis of the criteria from the European Renal Association-European Dialysis and Transplant Association CKD guidelines 2 : estimated glomerular filtration rate (GFR) of less than 60 mL/min, the presence of markers of kidney damage, such as a urinary albumin-to-creatinine ratio of greater than 30 mg/g for more than 3 months, or both. The participants in the control group were either healthy volunteers or patients with no history of renal disease, without diabetes mellitus or hypertension, with an estimated GFR of greater than 60 mL/min and no urinary sediment abnormalities in the previous 3 months.
All participants had previously undergone a conventional renal US examination, and we excluded those who had a kidney length of less than 10 cm, a renal parenchymal thickness of less than 1 cm, or a difference between the two kidneys of greater than 1.5 cm and participants who had renal structural abnormalities, lithiasis, or tumors. Patients undergoing renal replacement therapies (peritoneal dialysis, hemodialysis, or renal transplant) were not included in our study.
For all of our patients with CKD, we recorded the age, sex, body mass index (BMI), presence/absence of diabetes mellitus, presence/absence of hypertension, underlying causes of CKD (if present), estimated GFR, and proteinuria. We calculated the estimated GFR using the Chronic Kidney Disease Epidemiology Collaboration formula, 17 and patients with CKD were classified as follows: G1, estimated GFR of greater than 90 mL/min; G2, estimated GFR of 60 to 89 mL/min; G3, estimated GFR of 30 to 59 mL/min; G4, estimated GFR of 15 to 29 mL/min; and G5, estimated GFR of less than 15 mL/min. As per the definition, stages G1 and G2 (estimated GFR > 60 mL/min) had other markers of renal damage (albumin excretion rate > 30 mg/24 h and histologic abnormalities) documented for more than 3 months.
All participants included in our study signed an informed consent form. The study was approved by the local Ethics Committee and was conducted in accordance with the Declaration of Helsinki of 1975.
ElastPQ Assessment
We performed the EPQ technique incorporated in an Affiniti 70 US system (Philips Healthcare) with a convex array C5-1 transducer.
The participants were placed in the right and left decubitus positions. The operator applied minimal pressure to the transducer while the participant maintained temporary apnea to reduce breathing motion. A regionof-interest measuring box of 10 3 5 mm was placed in the midportion of the kidneys, perpendicular to the kidney capsule, and away from vessels or renal pyramids ( Figure 1 ). The operator aimed for 5 valid measurements in each kidney, quantified in meters per second on the screen. If the measurement was unsuccessful, the inscription 0.00 was displayed. In addition, if we could not obtain 5 valid measurements after 15 determinations, the evaluation was considered a failure.
Virtual Touch Quantification Assessment
The VTQ assessment was performed on the same day with an Acuson S2000 US system (Siemens AG), software version 2.0, with a 4C1 1.6-MHz convex transducer. The examination position was identical to the ElastPQ assessment, as was the position of the region-of-interest box, which had a predefined size of 10 3 5 mm. The evaluation was performed by the same operator who performed the ElastPQ assessment, targeting 5 valid measurements in each kidney. If the measurement obtained was invalid, the symbol 0.00 was displayed on the screen ( Figure 2 ). Similar to the EPQ technique, if 5 valid measurements were not obtained after 15 attempts, the investigation was considered a failure.
Statistical Analysis
We used MedCalc Software, version 12.5.0 (MedCalc, Mariakerke, Belgium) for the statistical analysis. The Kolmogrov-Smirnov test was used to assess the distribution of numeric variables. For variables with a normal distribution, we calculated the means and standard deviations, and we calculated the medians and ranges for non-normal numeric variables. For group comparisons of continuous variables with a normal distribution, we used Student t tests, and we used Mann-Whitney U tests for variables with a non-normal distribution.
For the correlation between EPQ and VTQ measurements, we used the Spearman rank correlation test. We used a 1-way analysis of variance (ANOVA) to compare EPQ measurements according to CKD stage and comorbidities (diabetes mellitus or hypertension).
The areas under the receiver operating characteristic curves (AUROCs) were calculated for EPQ to identify measurement cutoffs for an estimated GFR of less than 60 mL/min/1.73 m The optimal values were obtained with the Youden index (sensitivity 1 specificity -1) from the receiver operating characteristic curve analysis. Sensitivity and specificity values were determined as well. P < .05 was considered significant for each test applied. 
Results
We included a study group of 102 participants with CKD in whom we performed renal elastography using EPQ and a control group of 22 participants without CKD. We performed VTQ measurements in 91 patients. The characteristics of the groups are presented in Table 1 .
Valid EPQ SWV measurements for the right kidney were obtained in 122 of 124 participants (98.3%) and 116 of 124 participants (93.5%) for the left kidney. Valid VTQ values were achieved for the right kidney in 91 of 91 participants (100%) and in 86 of 91 participants (94%) for the left kidney. We aimed for 5 valid measurements after 15 attempts with both methods, bearing in mind that this protocol was used in previous studies as well. 11, 18 The mean SWV values were not significantly different between both kidneys for either EPQ (right kidney, 1.08 6 0.38 m/s; left kidney, 1.01 6 0.37 m/s; P 5 .38) or VTQ (right kidney, 2.12 6 0.3 m/s; left kidney, 1.97 6 0.23 m/s; P 5 .06).
The EPQ values for the control group were 1.23 6 0.33 m/s in the right kidney and 1.26 6 0.32 m/s (P 5 .6) in the left kidney, whereas in the patients with CKD (all stages), the means were 1.09 6 0.39 m/s in the right kidney and 1.04 6 0.38 m/s in the left kidney (P 5 .4), which were significantly lower than the control group. When clustering EPQ values for CKD patients with an estimated GFR of greater than 60 ml/min (stages 1 and 2), the value was lower than in the control group: 1.22 (right kidney) m/s and 1.08 (left kidney) m/s.
We performed correlations with different clinical and laboratory parameters (age, BMI, 24-hour proteinuria, and estimated GFR). We found no significant correlations between EPQ measurements and age in either the right kidney (r 5 0.04; P 5 .6) or the left kidney (r 5 0.13; P 5 .15). Furthermore, the EPQ values did not correlate either with proteinuria (right kidney, r 5 0.14; P 5 .15; left kidney, r 5 0.01; P 5 0.9) or with BMI values (right kidney, r 5 0.03; P 5 .68; left kidney, r 5 0.14; P 5 .12). When we compared the EPQ values between male and female participants, they did not differ. For the right kidney, the mean EPQ measurements were 1.12 6 0.37 m/s (female) and 1.04 6 0.4 m/s (male), and the difference was not significant (P 5 .72). For the left kidney, there were no differences between EPQ measurements in female and male participants. The mean was 1.01 6 0.37 m/s in both sexes.
For comorbidities, we performed 1-way ANOVAs to assess whether EPQ values differed in diabetic or hypertensive patients. The presence of either of these proved to be nonsignificant (P < .05 in both kidneys for both diabetes and hypertension). When we performed correlations between the estimated GFR and EPQ measurements, we obtained a significant direct correlation in the right kidney (r 5 0.34; P 5 .01) and the left kidney (r 5 0.3; P 5 .05; Figure 3) .
We used 1-way ANOVAs to compare mean kidney EPQ values in different CKD stages for both kidneys (CKD stage 1, 23 patients; CKD stage 2, 12 patients; CKD stage 3, 30 patients; CKD stage 4, 17 patients; and CKD stage 5, 13 patients). We obtained a significant difference (P 5 .04; Table 2 ) among CKD stages, with an obvious tendency for the SWV to decrease with the estimated GFR. We observed a direct, but weak, positive linear correlation between kidney SWV measurements using EPQ and VTQ (Spearman r 5 0.3; P 5 .01 for both kidneys). Data are presented as percent (number), median (range), and mean 6 SD where applicable.
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We performed correlations between VTQ measurements and demographic and laboratory data in both kidneys. We found indirect linear correlations between VTQ and BMI (right kidney, r 5 20.3; P 5 .009; left kidney, r 5 20.3; P 5 .009), age (right kidney, r 5 20.25; P 5 .01; left kidney, r 5 20.24; P 5 .01), and estimated GFR (right kidney, r 5 0.2; P 5 .05; left kidney, r 5 0.3; P 5 .01). There was no correlation between proteinuria and kidney stiffness (right kidney, r 5 20.01; P 5 .8; left kidney, r 5 20.01; P 5 .7).
The AUROCs of the EPQ measurements were calculated for different levels of CKD, with estimated GFR as the staging criterion. The EPQ method had sensitivity of 77.08% and specificity of 43.14% (P 5 .008) for a cutoff of less than 1.24 m/s in the case of patients with an estimated GFR of less than 45 mL/min. Using a cutoff of less than 1.07 m/s, EPQ could predict an estimated GFR of less than 30 mL/min with sensitivity of 72.73% and specificity of 51% (Table 3) .
Discussion
Currently, renal assessment by means of conventional US plays a minor role in the staging and diagnosis of CKD because it is a qualitative, subjective tool. There have been some attempts at characterizing renal echogenicity, parenchymal thickness, and renal length as markers of chronic disease. 19, 20 However, data are still scarce regarding the classifications and cutoff values.
Ultrasound elastography has emerged as a quantitative, noninvasive tool that has mostly been used for liver fibrosis assessment. 21 In the kidney, point SWE has been researched mainly by use of the VTQ technique, which showed that kidney SWV values decreased with the progression of CKD. 22, 23 Our study showed that it is possible to use EPQ to obtain similar rates of valid measurements as VTQ, and there is a positive, linear relationship between the methods.
When we investigated the factors influencing EPQ values, we observed no significant correlations with age, sex, BMI, or proteinuria. In studies performed with the VTQ technique on patients with all-cause CKD 23 and diabetic kidney disease, 24 BMI correlated inversely with kidney SWV values, as did age in the diabetic study group. We confirmed these results in our study.
The fact that the SWV values obtained with the EPQ technique are not influenced by age, sex, or BMI might give it greater utility and applicability with a smaller bias in clinical practice. These data were confirmed by a study performed by Singh et al, 18 who found the same lack of statistical significance between the EPQ kidney SWV and age, sex, BMI, and renal dimensions in a cohort with no renal disease. For the correlation with proteinuria, we obtained similar results as in the previously mentioned studies, 24 despite the fact that there are studies showing a relationship between proteinuria and the kidney SWV. 13 This finding might come across as interesting because of the well-established link between persistent proteinuria and renal fibrosis. 25 It has been shown that proteinuria, irrespective of its cause, triggers a process of fibrosis and CKD progression, which translates histologically into global glomerulosclerosis and tubulointerstitial matrix deposition. 26 When analyzing the studies correlating histologic factors and kidney SWV (all of them using the VTQ technique), the results are conflicting and inconsistent. Thus, Wang et al 27 showed no correlation between the histopathologic indicators of renal fibrosis and SWV measurements, whereas Hu et al 13 demonstrated a tendency for the SWV to decrease with the increase in overall histologic impairment. In a recent study by Gao et al 28 on quantitative US markers in relation to kidney biopsy findings, the findings with SWV were inconclusive.
It seems to be more widely demonstrated that with the VTQ technique, the SWV decreases with the estimated GFR. 12, 13, [22] [23] [24] 29 The best proposed cutoff value of 2.62 m/s predicted estimated GFR levels of less than 30 mL/min (CKD stage 4). 23 This finding implies that this method discriminates best in already advanced stages of renal impairment.
In our study, using the EPQ technique, we found the same pattern, but with a better correlation with the estimated GFR. In the controls, we obtained the following mean values: right kidney, 1.23 m/s; and left kidney, 1.26m/s. These values were lower than the ones recorded by Singh et al 18 in a cohort of 95 participants (right kidney, 1.49 m/s; left kidney, 1.51 m/s). This difference might have been due to the small control group in our study (22 participants as opposed to 95).
In patients with CKD, we proposed the cutoffs presented in Table 3 , which were statistically significant starting with a GFR of less than 45 mL/min, meaning CKD class 3b according to the Kidney Disease: Improving Global Outcomes study. This finding could indicate better clinical applicability than the VTQ technique in the general population. According to a recent meta-analysis performed by Hill et al 1 in 2016, it is estimated that the prevalence of stage 3 CKD in the general population is 7.6% compared with stages 4 and 5, at 0.4% and 0.1%, respectively. Despite the fact that there is no distinct prevalence data between CKD stages 3a (GFR 60-45 ml/min) and 3b (GFR 45-30 mL/min), it is estimated that a far greater percentage of patients are included in CKD stage 3b alone than in stages 4 and 5.
The heterogeneous patterns of histologic involvement in different types of renal disease (glomerular, vascular, and tubulointerstitial) as well as the anisotropy and high vascularization of the renal parenchyma might represent justifying factors for the lack of exact correlations between the SWV and each CKD stage. The renal cortex microstructure comprises an intricate architecture including glomeruli, Henle loops, collecting ducts, and a vast network of peritubular capillaries. All of these distinct histologic structures determine vascular and tubular interfaces and modify the speed of shear wave propagation. Thus, if a shear wave is emitted perpendicular to all of these histologic structures, its measured speed will be higher. 30 The underlying mechanism contributing to the progression of CKD is the rarefaction and destruction of this capillary network, leading to chronic hypoxia, inflammation, and fibrogenesis. Moreover, the compensatory angiogenesis is impaired and dysregulated in CKD, contributing to disease progression toward renal failure. 31, 32 An interesting hypothesis regarding the association between systemic advanced atherosclerosis, clinically translated as an increased pulsed wave velocity, and a lower kidney SWV shows the complexity of the factors affecting renal elasticity. This issue has been studied by Asano et al, 12 who performed brachial-ankle pulsed wave velocity measurements using a plethysmograph and demonstrated less kidney stiffness in patients with large-vessel arteriosclerosis. The limitations of our study include the relatively small sample size, mainly in the control group, and the lack of correlation with the histologic parameters proven on renal biopsies. The technique itself presents several limitations, including the fixed region-of-interest dimension (equal for both methods) and the need for placing it in the renal cortex, perpendicular to the renal capsule, in the midportion. This precise placement might come across as difficult in patients with a small parenchymal dimension, which often occurs in patients with advanced CKD. Another limitation of the study was the low specificity rates for CKD prediction. For the moment, elastography cannot replace the use of the estimated GFR for the staging of CKD, but its perspective is becoming a useful tool for patient screening in a clinical setting.
Magnetic resonance elastography is an up-andcoming method for renal fibrosis quantification in both native and transplanted kidneys. 33, 34 The data are promising regarding this method as well, but the costs, training, and availability of this method are bigger drawbacks to be considered than those of US elastography.
To conclude, point SWE using the EPQ technique is a novel, feasible method, and its results do not seem to be influenced by age, sex, BMI, or 24-hour proteinuria levels. The SWV values maintain their tendency to decrease with the progression of renal disease, as in VTQ. For an SWV of less than 1.24 m/s, we could predict the presence of an estimated GFR of less than 45 mL/min with sensitivity of 77.08% and specificity of 43.14%. For an estimated GFR of less than 30 mL/min, the proposed cutoff of 1.07 m/s had sensitivity of 72.73% and specificity of 51%. However, prospective studies are order to assess the variation of EPQ measurements in CKD advancement longitudinally.
